Results 61 to 70 of about 5,796 (217)

Genomic Insights Into Respiratory Syncytial Virus Circulation Patterns and Neutralization by Anti‐F Monoclonal Antibodies in Panama (2018–2024)

Influenza and Other Respiratory Viruses, Volume 19, Issue 10, October 2025.
ABSTRACT Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections and hospitalization in infants and children. Whole genome sequencing (WGS) plays a critical role in understanding the evolution and epidemiology of RSV.
Danilo Franco, Stephanie Goya, Alexander Martínez, Vicente Mas, Brechla Moreno, Elimelec Valdespino, Melissa Gaitán, Lisseth Sáenz, Claudia González, Ambar Moreno, Zeuz Capitan‐Barrios, Jean Paul Carrera, Sandra López‐Vergès, Juan Miguel Pascale, Yadira Moltó, Lourdes Moreno, Belmaris Rizo, Enrique Urriola, Teresa Delgado, María Iglesias‐Caballero, Inmaculada Casas, Suman R. Das, Juan Arbiza, Adriana Delfraro, Leyda Ábrego   +24 more
wiley   +1 more source

Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey

The Turkish Journal of Pediatrics, 2012
The main aim of this study was to evaluate the cost-effectiveness of respiratory syncytial virus (RSV) prophylaxis with palivizumab in Turkey, by comparing hospitalization rates and costs as well as results of risk analyses in preterm infants who ...
Mehmet Yekta Oncel, Banu Mutlu, Sumru Kavurt, Ahmet Yağmur Baş, Nihal Demirel, Mesut Akyol, Omer Erdeve, Uğur Dilmen   +7 more
doaj  

Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy

BMC Pediatrics, 2009
Background Bronchiolitis is a distressing, potentially life-threatening respiratory condition that affects infants. We evaluated the incidence and risk factors of hospitalization for broncholitis in preterm infants (i.e., a gestational age of
Mucchino Eleonora, Benincori Nicoletta, Mantovani Jessica, Pezzotti Patrizio, Di Lallo Domenico   +4 more
doaj   +1 more source

One‐year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America

Jornal de Pediatria (Versão em Português), 2017
Objective: This study aims to describe real world palivizumab use and effectiveness in high‐risk Latin American infants and young children. Method: Prospective, multicenter observational study with infants at risk for severe RSV infection who received ...
Leandro Martin Castillo, Gabriela Bugarin, Juan Carlos Arias, Jairo Israel Barajas Rangel, Maria Elina Serra, Nestor Vain   +5 more
doaj   +1 more source

Palivizumab for Respiratory Syncytial Virus Prophylaxis: Lessons Learned and Strategies for New Horizons [PDF]

, 2023
Giamberardino Hig, Webler Jm, Giamberardino Alg, Lucas A. Pereira, Raboni Sm   +4 more
openalex   +1 more source

Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia

BMC Infectious Diseases
Aim Palivizumab has proven effective in reducing hospitalizations, preventing severe illness, improving health outcomes, and reducing healthcare costs for infants at risk of respiratory syncytial virus (RSV) infection.
Jaime E. Ordóñez, Victor M. Huertas
doaj   +1 more source

Palivizumab for the Prophylaxis of Respiratory Syncytial Virus Disease: Expert Opinion and Recommendations for the Gulf Cooperation Council Region

Oman Medical Journal
Respiratory syncytial virus (RSV) infection poses a significant health threat to infants and young children. Considering the substantial burden in Gulf Cooperation Council (GCC) countries, prevention of RSV remains a major public health priority ...
Adel S. Alharbi, Abdul Rahman Alnemri, Ahmed Abushahin, Entesar Alhammadi, Huda Sulaiman Mohammed AlDhanhani, Laila Obaid , Mahmoud Saleh ElHalik, Mariam Kh Ayed   +7 more
doaj   +1 more source

Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children

, 2021
Luis Garegnani, Lea Styrmisdóttir, Pablo Rosón Rodríguez, Camila Micaela Escobar Liquitay, Ignacio Esteban, Juan Víctor Ariel Franco   +5 more
openalex   +2 more sources

Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease [PDF]

, 2009
Ruey‐Kang R. Chang, Alex Y. Chen
openalex   +1 more source

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season

BMC Pediatrics, 2010
Background Respiratory syncytial virus (RSV) is an important pathogen causing annual epidemics of bronchiolitis and pneumonia among infants worldwide.
Griffin M Pamela, Abarca Katia, Trenholme Adrian, Fernández Pilar, Hultquist Micki, Harris Brian, Losonsky Genevieve A   +6 more
doaj   +1 more source